- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01368224
Two Supplemented Against Skin Reactivity
PLACEBO-CONTROLLED STUDY OF THE EFFECT OF TWO FOOD SUPPLEMENTS ON SKIN REACTIVITY
In recent decades, the incidence of subjects presenting reactive skin has considerably increased in industrialized countries. Probiotics are live microorganisms which, when ingested in sufficient amounts, have beneficial effects on human health. The mechanism underlying the effect of probiotics involves, in part, regulation of the composition and/or metabolic activity of the intestinal microbiota.. It is postulated that following interaction of probiotics with the intestinal epithelium, associated intestinal cells become activated and consequently mediators are released into the blood circulation. Mediators, activated intestinal epithelial cells and possibly bacterial fractions might reach the skin through the bloodstream where they potentially could exert effects.The objective of this study was to assess the effects of probiotics on reactive skin symptoms. The strain Lactobacillus paracasei NCC2461 was tested alone and in combination with the strain Bifidobacterium longum NCC3001 in a randomized, double-blind study. The two strains were selected for their immune-modulatory properties demonstrated in in vitro and other preclinical studies as well as in a pilot clinical trial.
Ninety-six women presenting reactive skin were randomized to 3 groups: placebo (n = 32), L. paracasei NCC2461 alone (n = 32) and L. paracasei NCC2461 + B. longum NCC3001 (n = 32). The supplements were administered by the oral route for 58 days (1010 CFU/day).
The objective of the clinical trial was to determine, in vivo, the effect of food supplements on reactive skin symptoms (as measured by skin sensitivity and the reconstruction of barrier function post-repeated tape stripping).
The secondary objectives were to determine the effect of the food supplements on leg skin dryness and facial skin roughness and the associated biochemical, immunological and microbiological factors.
Accordingly, the subjects' skin sensitivity was determined by the capsaicin test. The reconstruction of barrier function was determined by measuring the trans-epidermal water loss (TEWL) post-repeated stripping using a SERVOMED evaporimeter. A clinical score for skin dryness and roughness was assigned by a dermatologist. The subjects also assessed their leg and facial skin dryness themselves. Each analysis was conducted at the various time points.
In parallel, assessment of the skin moisturizing factors and serum inflammatory and immune-regulatory cytokines were performed. Finally, key components of the intestinal microbiota were analyzed.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The probiotics and particularly Lactobacillus paracasei and Bifidobacterium longum are of value with respect to the homeostasis of dry and sensitive skin.
An initial study (study report No. 1020813, DERMSCAN dated 2/10/2004) showed that the combination of L. paracasei NCC2461 (ST11) with Bifidobacterium lactis NCC2818 (Bb12) induced an improvement in certain parameters related to skin reactivity. However, the probiotics have not been tested separately.
It was thus considered important to conduct a clinical trial aiming at confirming and documenting the data generated by the previous study and, also determining the specific efficacy of L. paracasei NCC2461 (ST11) on reactive skin symptoms. The latter probiotic strain was selected on the basis of its proven immune-modulatory properties (scientific dossier ST11-Nestec Benyacoub and Gueniche. Scientific evidence supporting the use of Lactobacillus paracasei NCC2461 (ST11) for Innéov. Report 11.02.2005 and references 23, 24, 31-33). The strain was combined or not with a probiotic of the Bifidobacterium genus, particularly Bifidobacterium longum NCC3001. The data generated by various preclinical studies (NRC in-house studies) and clinical studies (public) show that this probiotic strain is able to modulate immune mechanisms and could interfere with inflammatory reactions.
Moreover, the probiotic combination concept enables providing potential benefit all along the gastrointestinal tract, inducing maintenance of an optimum intestinal flora.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Villeurbanne, France, 69623
- DERMSCAN - Pharmascan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy subject.
- Gender: female.
- Subject aged more than 18 years and less than 35 years (inclusive)
- Phototype: I to IV
- Caucasian race.
- For women of child-bearing potential, effective contraception for at least 12 weeks and maintained throughout the study and for 1 month after completion of the study.
- Sensitive skin: (1) as per the subjective evaluation questionnaire in appendix 12.2. (with at least 1 positive response to one of the first 3 questions) and (2) responder to the capsaicin test at one of the 3 lowest concentrationsSubject known to have dry leg skin (clinical score of at least 2 as per the scale).
- Subject known to have rough cheek skin (clinical score of at least 3 as per the scale).
- Low consumers of fermented dairy products (less than 125 g/d) and agreeing not to eat fermented dairy products containing live bacteria (yogurt, cottage cheese, fermented dairy products, unpasteurized cheese, etc.) for the duration of the study.
Exclusion Criteria:
- Post-menopausal woman.
Pregnant or breast-feeding woman or woman planning pregnancy during the study.
--Volunteer with a skin disease in the test areas (particularly acne rosacea). Volunteer presenting a stable or progressive serious disease (investigator's assessment).
- Immunocompromised subject.
- Subject allergic to one of the constituents of the test products and, in particular, capsaicin or pepper.
- Alcohol intake greater than 2 glasses of wine daily or 1 glass of liquor daily.
- Smoker of more than 6 cigarettes/day.
- Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
- Subjects regularly practicing aquatic or nautical sports.
- Subjects regularly attending a sauna.
- Subject with cardiovascular or circulatory history.
- Subject with a history of skin cancer or malignant melanoma.
- Subject with a history of intestinal surgery.
- Intake of antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune-suppressants.
- Subject practicing sports for more than 5 hours per week.
- Subject having taken mineral or vitamin supplements in the 3 months preceding the study (investigator's assessment).
- Lacto-ovo-vegetarian, vegetarian.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Maltodextrin
|
1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit. Oral route. |
Experimental: Lactobacillus paracasei NCC 2461 (ST 11)
1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11)
|
1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit. Oral route. |
Experimental: Lactobacillus paracasei+ Bifidobacterium longum
1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11) + 1x1010 CFU of Bifidobacterium longum (NCC3001)
|
1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit. Oral route. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
---|---|
skin sensitivity and skin barrier reconstruction
|
determining the effect of food supplements on skin reactivity (measured by skin sensitivity and the skin barrier function reconstruction after repeated tape-stripping).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
---|---|
dryness , roughness, biochemical factors and safety
|
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1040341
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Sensitivity
-
Ventrus Biosciences, IncUnknown
-
University of PalermoAurelio SeiditaRecruiting
-
L'OrealRecruitingSunscreen Sensitivity | Ultraviolet-Induced Change in Normal SkinRomania
-
Galderma R&DCompletedDetermine Sensitivity of Skin to Cetaphil Daily Advance Ultra Hydrating Lotion
-
University Hospital, Gentofte, CopenhagenCompletedInsulin Sensitivity | Metabolism DisorderDenmark
-
University of CopenhagenRecruitingBreast Cancer | Insulin Sensitivity/Resistance | Metabolic Disturbance | SurvivorshipDenmark
-
Universidade Federal do ParaCompletedColor | Bleaching SensitivityBrazil
-
Herbarium Laboratorio Botanico LtdaCompletedSensitivity, ContactBrazil
-
Herbarium Laboratorio Botanico LtdaCompletedSensitivity, ContactBrazil
-
UNION therapeuticsCompleted
Clinical Trials on Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001
-
National Health Service, United KingdomFerring Pharmaceuticals; Hull University Teaching Hospitals NHS Trust; North... and other collaboratorsCompleted
-
Société des Produits Nestlé (SPN)CompletedMood Change | Perinatal Problems | Stress-related ProblemSingapore
-
KGK Science Inc.Lallemand Health SolutionsCompletedIrritable Bowel SyndromeCanada
-
Universidad Católica San Antonio de MurciaCompleted
-
ProbiSearch SLLallemand Health SolutionsCompletedBody Weight | Body Height | Head CircumferenceSpain
-
University of FloridaLallemand Human NutritionCompleted
-
University of FloridaWakunaga Pharmaceutical Co., Ltd.CompletedHealthyUnited States
-
Fundación IVIInstituto Valenciano de Infertilidad, IVI VALENCIA; Biopolis S.L.; ADM ProtexinRecruitingMale InfertilitySpain
-
University of Wisconsin, MadisonNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedClostridium DifficileUnited States
-
University of FloridaWakunaga Pharmaceutical Co., Ltd.Completed